Binghamton University will play a key role in a federal grant of up to $42.8 million to develop an implantable device that acts as a living pharmacy to treat inflammatory diseases.

The study emphasises on the role of the p53 tumor suppressor gene in the pathogenesis of ulcerative colitis - an inflammatory ...

Binghamton University, State University of New York will play a key role in a federal grant of up to $42.8 million to develop ...

Mirikizumab, a drug currently approved by the Food and Drug Administration (FDA) for the treatment of ulcerative colitis, ...

For millions of Americans, paying for the treatment needed to manage their diseases can become its own lifelong problem.

A joint presentation by an endocrinologist and ophthalmologist reviewed best practices for managing thyroid eye disease, ...

The use of glucagon-like peptide 1 (GLP-1) agonists in patients with inflammatory bowel disease (IBD) was associated with few ...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that it has initiated ...

Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as ...

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering ...

There are around 44,100 new bowel cancer cases in the UK every year with symptoms generally not developing until the disease ...